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ATAT1-enriched vesicles promote microtubule 
acetylation via axonal transport
Aviel Even1*, Giovanni Morelli2,3*, Loïc Broix2*, Chiara Scaramuzzino4,5, Silvia Turchetto2, 
Ivan Gladwyn-Ng2, Romain Le Bail2, Michal Shilian1, Stephen Freeman2, Maria M. Magiera6,7, 
A. S. Jijumon6,7, Nathalie Krusy2, Brigitte Malgrange2, Bert Brone3, Paula Dietrich8, 
Ioannis Dragatsis8, Carsten Janke6,7, Frédéric Saudou4,5,9, Miguel Weil1*†, Laurent Nguyen2*†
Microtubules are polymerized dimers of - and -tubulin that underlie a broad range of cellular activities. Acetylation 
of -tubulin by the acetyltransferase ATAT1 modulates microtubule dynamics and functions in neurons. However, 
it remains unclear how this enzyme acetylates microtubules over long distances in axons. Here, we show that loss 
of ATAT1 impairs axonal transport in neurons in vivo, and cell-free motility assays confirm a requirement of -tubulin 
acetylation for proper bidirectional vesicular transport. Moreover, we demonstrate that the main cellular pool of 
ATAT1 is transported at the cytosolic side of neuronal vesicles that are moving along axons. Together, our data 
suggest that axonal transport of ATAT1-enriched vesicles is the predominant driver of -tubulin acetylation in axons.
INTRODUCTION
Neurons are polarized cells, structurally and functionally divided into 
somatodendritic and axonal compartments. Axons are often long and 
characterized by intense bidirectional microtubule (MT)–dependent 
transport of cargos to control critical functions, including cell sur-
vival and neurotransmission. Cargos such as vesicles and membrane 
organelles (e.g., mitochondria, endosomes, and lysosomes) as well 
as proteins and messenger ribonucleoprotein complexes are loaded 
on molecular motors to undergo axonal transport along MTs. The 
anterograde transport is powered by the kinesin superfamily, while 
retrograde transport involves cytoplasmic dynein (1). Posttransla-
tional modifications (PTMs) of MTs have been suggested to modu-
late axonal transport (2, 3). Specifically, the acetylation of MTs may 
contribute to this process by enhancing the recruitment of kinesin 
and dynein and their mobility (4, 5). Moreover, increasing MT acetyl-
ation improves the transport deficits resulting from mutations in 
Huntingtin and LRRK2 genes (4, 6). The acetylation of -tubulin in 
MTs is driven by the -tubulin N-acetyltransferase 1 (ATAT1)/MEC17 
(7, 8). Recent in vitro experiments performed with recombinant ATAT1 
have suggested that it can enter the lumen of MTs from their extrem-
ities and/or lateral imperfection (9, 10) and passively diffuses to 
promote acetylation of -tubulin K40 residues (11, 12). However, it 
remains unclear how ATAT1 reaches and acetylates MTs in living 
cells. This question is particularly important in neurons where 
axons and dendrites cover long distances with rather homogenously 
acetylated MTs. To decipher how ATAT1 promotes MT acetylation 
in neurons, we combined cell-free assays with cellular and molecular 
analyses of ex vivo (organotypic slices) or cultured mouse cortical 
projection neurons (in microfluidic chambers) and motoneurons of 
Drosophila larvae in vivo. Our work unveils the existence of a pre-
dominant pool of ATAT1 at the cytosolic side of motile vesicles, 
whose active transport promotes acetylation of -tubulin in MTs. 
Therefore, we propose that the transport of ATAT1-enriched vesicles 
is a predominant driver of axonal MT acetylation.
RESULTS
Loss of Atat1 interferes with axonal transport in  
neurons across species
ATAT1 promotes the acetylation of -tubulin in MTs, a PTM that 
favors the recruitment of kinesin and dynein and their mobility along 
axons (4, 5, 13). To test whether loss of Atat1 impairs axonal trans-
port in cortical projection neurons in situ, we performed time-lapse 
recordings of organotypic brain slices from postnatal (P) day 2 
wild-type (WT) mice. For this purpose, embryonic day 14.5 (E14.5) 
mouse embryos were in utero electroporated (IUE) with a combina-
tion of 4OH-tamoxifen (4OHT)–inducible Cre, Cre-inducible short 
hairpin RNA against Atat1 (shAtat1) (fig. S1A), Cre-inducible red 
fluorescent protein, and Lamp1-Emerald plasmids. Successive in-
jections of 4OHT allowed us to identify the callosal projection of 
IUE neurons and record the transport of Lamp1-Emerald–positive 
lysosomes (Fig. 1, A and B, and movie S1). We showed that the 
4OHT-induced knockdown (KD) of Atat1 in callosal projection 
neurons 3 days after IUE at E14.5 (to maintain the expression of 
Atat1 during the migration of projection neurons) impaired both 
anterograde and retrograde axonal transports recorded at P2 
(Fig. 1, A to F, and fig. S1B). The KD of Atat1 led to the reduction 
of the average and instantaneous velocities (Fig. 1, C and D) and the 
run length and to the increase of the pausing time of lysosomes 
(Fig. 1, E and F). These data were confirmed in cortical projection 
neurons from E14.5 Atat1 knockout mice (Atat1 KO) or their cor-
responding WT controls (14) cultured for 5 days in vitro (DIV) in 
microfluidic devices and incubated with fluorescent probes to fol-
low the transport of lysosomes and mitochondria along axonal MTs 
(Fig. 1, G and H, and movies S2 and S3). The average velocities 
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Fig. 1. Depletion of Atat1 prevents acetylation of -tubulin and interferes with fast axonal transport of organelles ex vivo and in vitro. (A) Experimental setup 
used to perform axonal transport recordings in organotypic brain slice. (B) Labeling of lysosome Lamp1-Emerald+ (green) and inducible dsRed (red) in axons crossing the 
corpus callosum of a P2 mouse cortical section. Scale bars, 200 m (top) and 10 m (bottom). (C to F) Histograms showing axonal transport parameters of Lamp1-Emerald 
(lysosomes) to analyze average velocity (C), instantaneous velocity (D), run length (E), and pausing time (F). (G) Microfluidic device setup used for recording axonal transport 
in cortical neurons. (H) Labeling of lysosomes and mitochondria with fluorescent probes (LysoTracker and MitoTracker) in cortical neurons cultured 5 DIV and isolated 
from E14.5 WT or Atat1 KO mouse embryos. Scale bars, 50 m. (I to L). Histograms showing parameters of axonal transport of lysosomes to analyze average velocity 
(I), instantaneous velocity (J), run length (K), and pausing time (L) of mouse cortical neurons transfected with GFP or ATAT1-GFP, cultured 5 DIV, and isolated from E14.5 from 
WT or Atat1 embryos. (M) Experimental setup for time-lapse recording of axonal transport in E15.5 cortical neurons isolated from E14.5 IUE mouse embryos and cultured 5 days 
in microfluidic device. N.S., not significant. (N to Q) Histograms showing parameters of axonal transport of lysosomes (LysoTracker) to analyze average velocity (N), instantaneous 
velocity (O), run length (P), and pausing time (Q) in mouse cortical neurons cultured 5 DIV from E15.5 embryos transfected with WT -tubulin GFP (Tub-GFP) or acetylation mimic 
K40Q -tubulin GFP (K40Q Tub-GFP) together with sh-Scramble (sh-Scr) or sh-Atat1. Description of graphical summaries here within are histograms of means ± SEM, while 
statistical analyses of (C to F) are two-tailed Mann-Whitney and (I, J, K, L, N, O, P, and Q) are Kruskal-Wallis test. Specifically [(C) P < 0.0001 and U = 17,455; (D) P < 0.0001 and 
U = 3044 and P = 0.0002 and U = 6372 for anterograde and retrograde, respectively; (E) P < 0.0001 and U = 20,972; (F) P < 0.0001 and U = 26,168; (I) P < 0.0001 and K = 54.03; 
(J) P = 0.0033 and K = 13.74 and P < 0.0001 and K = 36.45 for anterograde and retrograde, respectively; (K) P < 0.0001 and K = 38.29; (L) P < 0.0001 and K = 34.05; (N) P < 0.0001 and 
K = 31.88; (O) P = 0.0006 and K = 17.43 and P = 0.0002 and K = 20.19 for anterograde and retrograde, respectively; (P) P < 0.0001 and K = 22.29; and (Q) P < 0.0001 and K = 28.7).
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(Fig. 1I and fig. S1, G, M, N, and R), anterograde and retrograde 
instantaneous velocities (Fig. 1J and fig. S1, H, M, N, and R), and 
run lengths (Fig. 1K and fig. S1, I, M, N, and R) of moving vesicles 
and mitochondria were reduced, while their pausing time were in-
creased (Fig. 1L and fig. S1, J, M, N, and R). These modified vesicular 
parameters were associated with an impairment in the overall flux 
of organelles in Atat1 KO mice (fig. S1, K, L, M, and N), likely arising 
from the reduced recruitment of motors onto MTs. Western blot-
ting analyses revealed that lack of ATAT1 expression in newborn 
cortical neurons resulted in the absence of MT acetylation (fig. S1, 
O and P) without affecting the expression level of histone deacetylase 6 
(HDAC6), the main -tubulin deacetylase (fig. S1, O and Q). Expres-
sion of catalytically active ATAT1–green fluorescent protein (GFP) 
(15, 16) in cortical neurons from E14.5 WT and Atat1 KO embryos 
rescued the average velocity (Fig. 1I and fig. S1R), anterograde and 
retrograde instantaneous velocities (Fig. 1J and fig. S1R), run length 
(Fig. 1K and fig. S1R), and pausing time (Fig. 1L and fig. S1R) of 
lysosomes. To confirm that the defects in axonal transport upon 
down-regulation of Atat1 arise from reduced -tubulin acetylation, we 
coexpressed the acetyl mimic -tubulin K40Q with shAtat1 (fig. S1S) 
in projection neurons of WT E14.5 embryos. We isolated the electro-
porated neurons 1 day after electroporation and cultured them 5 days 
in microfluidic devices (Fig. 1M). Our recordings showed that ex-
pression of -tubulin K40Q rescued the average and instantaneous 
transport velocities of lysosomes (Fig. 1, N and O, and fig. S1X) and 
mitochondria (fig. S1, T, U, and Y), as well as their run lengths 
(Fig. 1P and fig. S1, V, X, and Y) and pausing time (Fig. 1Q and fig. S1, 
W, X, and Y) resulting from Atat1 KD at E14.5.
We further examined whether the role of ATAT1 in axonal trans-
port is conserved in vivo in Drosophila melanogaster. We assessed 
the transport of synaptotagmin-GFP vesicles in axons of third-instar 
larva motoneurons (Fig. 2, A and B, and movie S4) upon RNA inter-
ference (RNAi)–mediated KD of Atat1/2 (the orthologs of mouse 
Atat1 in D. melanogaster). Individual KDs of Atat1 and Atat2 were 
not compensated by expression of other -tubulin acetylation regu-
lators (fig. S2, A and B) and led to the reduction of average velocity 
(Fig. 2C and fig. S2C), anterograde and retrograde instantaneous 
velocities (Fig. 2D and fig. S2C), as well as run length (Fig. 2E and 
fig. S2C) of synaptotagmin-GFP vesicles, with associated increase of 
their pausing time (Fig. 2F and fig. S2C). The transport defects were 
not resulting from global protein aggregation along axons (fig. S2D) 
but were more likely associated with the decreased acetylation of 
MTs (Fig. 2, G and H). This was further supported by a genetic rescue 
of axonal transport upon concomitant depletion of the main -tubulin 
deacetylase Hdac6 (17) (fig. S2E) in motoneurons from individual 
KD of Atat1 or Atat2 larva (Fig. 2, C to F, and fig. S2C), where re-
sidual Atat activity can promote MT acetylation (Fig. 2, G and H). 
These data were also supported in the third-instar larvae fed 
for 30 min before recordings with 10% sucrose solution contain-
ing tubastatin (TBA), a specific inhibitor of HDAC6 (18), which 
rescued all measured axonal transport parameters (Fig. 2, I to L, 
and fig. S2F).
Impaired axonal transport in larvae or adult fly motoneurons 
leads to locomotor behavior deficits (18). We thus monitored the 
climbing index of adult flies as well as the crawling speed and peri-
staltic body-wave frequency of their larvae as functional readouts 
of single or combined KD of Atat1/2 (6, 19). These motoneuron- 
dependent activities were affected upon conditional KD of Atat1/2 
expression (Fig. 2, M to O) and were rescued by either a concomitant 
genetic depletion of Hdac6 (Fig. 2, M to O) or inhibition of HDAC6 
activity using TBA (Fig. 2, P and Q). The disruption of motor be-
haviors was most likely a consequence of fast axonal transport 
defects, since we did not observe morphological changes at the neuro-
muscular junctions’ synapses (fig. S2, G and H) and the RNAi-mediated 
KD was restricted to motoneurons (see Materials and Methods). 
Together, these data support that ATAT1 promotes the acetylation 
of axonal MTs across vertebrate and invertebrate species and that 
acetylation of the MTs tracks is an important regulator of fast 
axonal transport.
We next assessed in a cell-free in vitro molecular transport assay 
how the reduction of K40 acetylation on MTs affects bidirectional 
axonal transport. For this purpose, purified vesicles were added to 
in vitro polymerized and polarity-marked MTs (to determine trans-
port directionality), where 10% of rhodamine-labeled (acetylated) 
tubulin were mixed with either unacetylated tubulin from Atat1 KO 
mouse brains or with endogenously acetylated tubulin from WT 
littermates (control) (Fig. 3, A and B, and movie S5). While MTs from 
Atat1 KO mouse brains were lacking acetylation (20), they were not 
showing defects of polyglutamylation, glutamylation, tyrosination, 
or the abundance of 2 tubulin PTMs (Fig. 3C). In vitro transport 
analyses showed that vesicles’ anterograde and retrograde instanta-
neous velocities (Fig. 3D and fig. S3A), together with their run lengths 
(Fig. 3E and fig. S3A), were reduced when vesicles were transported 
along Atat1 KO brain-derived MTs as compared with acetylated 
MTs isolated from WT brains. These data were comparable to the 
one obtained in neurons in vitro and in vivo (Figs. 1, D and E, and 2, 
D and E) and further demonstrate that loss of -tubulin K40 acetyl-
ation impairs MT-dependent transport.
Atat1 is transported along MTs at the external surface 
of motile vesicles
Axons and dendrites are highly enriched in long-lived MTs, whose 
acetylation depends on ATAT1 distribution and activity. In vitro 
experiments have previously reported that recombinant ATAT1 
undergoes slow and passive diffusion inside MT lumen (12). However, 
it remains unclear how ATAT1 reaches the MTs in living neurons; 
thus, we studied its axonal distribution in cultured cortical neurons 
isolated from E14.5 mice. Mouse cortical neurons were transfected 
with a combination of plasmids coding for brain-derived neuro-
trophic factor (BDNF)–mCherry and ATAT1-GFP and cultured 
5 DIV. Analysis by superresolution microscopy revealed a punctate 
distribution of ATAT1 along axons, partially overlapping with the 
dense core vesicle marker BDNF, suggesting a possible vesicular 
enrichment of ATAT1 (Fig. 4A). The vesicular enrichment of ATAT1 
was further confirmed in cultured human projection neurons derived 
from pluripotent stem cells, showing that expression of endogenous 
ATAT1 broadly codistributes with lysosomes (LAMP1 positive) and 
precursors of synaptic vesicles (SV2C and synaptophysin positives) 
along their axon (Fig. 4B).
To confirm the vesicular expression of ATAT1, we performed 
liquid chromatography–tandem mass spectrometry (LC-MS/MS) 
on vesicular extracts isolated from the cortex of newborn mice. The 
analysis of the vesicular enriched fraction detected 3648 proteins 
whose overlap with published vesicular proteomes was, in average, 
75% (21–23) (Fig. 4C). These analyses showed that ATAT1, but not 
HDAC6, is detected together with kinesins and dyneins in a mid-
range fraction of the vesicular proteomic content (Fig. 4D and table 
S1). Western blot analysis of the subcellular fractions obtained from 







Even et al., Sci. Adv. 2019; 5 : eaax2705     18 December 2019


































































































































































































































































































































































































































































































































































































































































































Fig. 2. Depletion of Atat1 prevents acetylation of -tubulin and interferes with fast axonal transport of organelles in vivo. (A and B) In vivo live-imaging setup 
used to record axonal transport of synaptotagmin-GFP (SYT1-GFP in green) in D. melanogaster third-instar larvae expressing UAS:RNAi under a motoneuron-specific 
driver (D42:GAL4) to analyze average velocity (C), instantaneous velocity (D), run length (E), and pausing time (F). (G and H). Analyses of immunolabeled motoneurons 
from third-instar larvae to detect total -tubulin (Tot -tub) and acetylated -tubulin (Ac -tub). Scale bars, 10 m. (I to L) Axonal transport recording in Atat1;Atat2 KD 
third-instar larvae fed for 30 min before recording with 10% sucrose with 1 mM TBA or dimethyl sulfoxide (DMSO) to measure SYT1-GFP average velocity (I), instantaneous 
velocity (J), run length (K), and pausing time (L). (M and N) Larva peristaltic movements and crawling speed in third-instar larvae expressing RNAi under a motoneuron- 
specific driver (D42:GAL4). (O) Climbing index in adult flies expressing RNAi under a motor neuron-specific driver. (P and Q) Larva peristaltic movements and crawling 
speed in third-instar larvae expressing RNAi under a motoneuron-specific driver (D42:GAL4) or in control and Atat1;Atat2 KD larva prefed for 30 min with 10% sucrose with 
1 mM TBA or DMSO. Description of graphical summaries here within are histograms of means ± SEM, while statistical analyses of (C, D, E, F, H, I, J, K, and L) are Kruskal-Wallis 
and (M to Q) is one-way analysis of variance (ANOVA). Specifically [(C) P < 0.0001 and K = 60.10; (D) P < 0.0001 and K = 65.80 and P < 0.0001 and K = 76.02 for anterograde 
and retrograde respectively; (E) P < 0.0001 and K = 25.39; (F) P < 0.0001 and K = 9.6; H, P < 0.0001 and K = 30.09; (I) P < 0.0001 and K = 121.1; (J) P < 0.0001 and K = 62.57 
and P < 0.0001 and K = 50.34 for anterograde and retrograde, respectively; (K) P < 0.0001 and K = 24.3; (L) P < 0.0001 and K = 12.96, M, P < 0.0001 and F(4, 58) = 34.55; (N) 
P < 0.0001 and F(4, 55) = 40.83; (O) P < 0.0001 and F(4, 33) = 45.61; (P) P < 0.0001 and F(7, 71) = 27.29; and (Q) P < 0.0001 and F(7, 83) = 47.65]. In addition, post hoc multiple 
comparisons for (C, D, E, F, I, J, K, L, and H) Dunn’s tests, for (M to Q) is Dunnett’s test and are *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. The total number of 
samples analyzed were as follows: (C to F) 110 to 276 vesicle tracks from 7 to 12 larvae per group; (H) 6 to 8 larvae per group; (I to L) 112 to 161 vesicle tracks from at 6 to 
8 larvae per group; (M and N) 9 to 18 larvae per group; (O) 6 to 11 assays per group; and (P and Q) 8 to 9 larvae per group.
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protein extract of newborn mouse brains confirmed the selective 
enrichment of ATAT1 in the vesicular fraction (P3), contrasting with 
the predominant cytosolic distribution of HDAC6 (S3) (Fig. 4E). 
Moreover, time-lapse recordings showed that ATAT1-GFP clusters 
move bidirectionally together with lysosomes (LysoTracker, Fig. 4F) 
and dense core vesicles (BDNF-mCherry, Fig. 4F) at velocities that 
are consistent with axonal transport in transfected cortical projection 
neurons (Fig. 4, G and H, and movie S6) (24). These data demon-
strate that ATAT1 is enriched in the vesicular fraction and that it is 
transported along axons by motile vesicles.
ATAT1 binds to clathrin-coated vesicles via an AP2 binding 
domain (amino acids 307 to 387) (25), which is only conserved by 
its isoforms 1 and 2 (Fig. 4I). Our LC-MS/MS analysis did not 
detect peptides corresponding to the AP2 binding domain of ATAT1 
in purified vesicles extracts (fig. S4A), and Western blott (WB) per-
formed on mice cortical brain extracts only detected the presence 
of ATAT1 isoforms 3 and 4 (Fig. 4E), suggesting that the AP2 bind-
ing domain is not required for the recruitment of ATAT1 to motile 
vesicles.
To identify ATAT1’s vesicle binding domain, we engineered dis-
tinct truncated ATAT1 forms by deleting amino acid sequences be-
tween the minimal catalytic domain of ATAT1 (amino acids 1 to 196) 
and the C-terminal part of isoform 4 (amino acids 1 to 333) (Fig. 4I). 
These constructs were next used to transfect human embryonic kid-
ney (HEK) 293 cells and analyzed for their subcellular localization 
by WB (Fig. 4, J and K). ATAT1 isoform 4 and its amino acid 1 to 
286 truncation were enriched in vesicles [vesicles (P3)/cytosol frac-
tion ratio (S3) > 1], while the other truncated forms (1 to 242 and 1 
to 196) preferentially localized in the cytosol (P3/S3 < 1) (Fig. 4K). 
Moreover, expression of the vesicular-enriched ATAT1 isoforms was 
more efficiently raising the level of -tubulin acetylation when ex-
pressed in HeLa S3 cells as compared to the others (Fig. 4, L and M). 
Together, these data suggest that the amino acid sequence of ATAT1 
comprised between amino acids 242 to 333 is required for both its 
vesicular enrichment and efficient -tubulin acetylation.
To decipher whether ATAT1 is encapsulated within the intra-
vesicular lumen and/or associated with the extravesicular membrane, 
we performed a mild proteinase K digestion to remove protein an-
chored at the external surface of vesicles (26). The treatment led to 
a dose-dependent reduction of ATAT1 and dynein intermediate 
chain (DIC) without altering levels of the intravesicular protein 
-synuclein (Fig. 4N) (26). Together, these data suggest that ATAT1 
is enriched at the cytosolic side of moving vesicles, from where it 
may be released in vicinity of MTs to promote -tubulin acetylation 
and modulate axonal transport.
The vesicular pool of Atat1 controls axonal transport by 
promoting acetylation of MTs
We first performed LC-MS/MS on vesicular extracts isolated from 
the cortex of newborn WT or Atat1 KO mice to check whether loss 
of Atat1 interferes with axonal transport by altering the vesicular 
proteome. The analysis revealed that, from 44 differentially detected 
proteins (fig. S5A and table S2), none of the 29 molecular motor 
proteins (fig. S5B and table S3) nor the 16 glycolytic enzymes (fig. 
S5C and table S4) were significantly affected by lack of Atat1 
expression. Moreover, gene ontology (GO) data analysis of the dif-
ferentially detected proteins did not reveal significantly enriched 
processes, function, or cellular component upon Atat1 loss in 
vesicular extracts. Since we did not detect any differences of the Atat1 
KO vesicular proteome that can explain the reduction of MT acetyl-
ation, we hypothesized that Atat1-enriched vesicle displacement 
on MTs might be required for their acetylation. To test this hypothesis, 
we cultured mouse cortical neurons with the cytoplasmic dynein 
inhibitor ciliobrevin D (20 M) (27) to disrupt axonal transport of 
vesicles. This led to a mild reduction (33%) of MT acetylation in the 










































































Fig. 3. Vesicle transport is reduced on nonacetylated MTs in vitro. (A) Scheme representing the experimental setup to study in vitro transport and acetylation assays. 
(B) Total internal reflection fluorescence (TIRF) image series of rhodamine-labeled MTs (10%, purple) with a transported DIO (green)–labeled vesicle from mouse brains. Scale bar, 
2 m; presented frames are in a 400-ms interval. (C) Western blott (WB) analyses to detect acetylated, glutamylated, polyglutamylated detyrosinated, 2, or total -tubulin (Tub) 
in cortical brain extracts of WT or Atat1 KO adult mice. (D and E) In vitro transport assay of vesicles purified from WT mice with nonacetylated -tubulin from Atat1 KO 
mouse brain or endogenously acetylated -tubulin from WT mice. Histogram of anterograde and retrograde instantaneous velocities (D) and run length (E) of moving 
vesicles. Description of graphical summaries here within are histograms of means ± SEM, statistical analyses of (D) and (E) are two-tailed t test. Specifically [(D) P = 0.0299 
and t, df(2,273,32) and P = 0.0054 and t, df(2,971,34) for retrograde and anterograde, respectively; and (E) P = 0.0086 and U = 50]. The total number of samples analyzed 
were as follows: (D and E) 16 to 20 vesicles from three WT or Atat1 KO mice.
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Fig. 4. ATAT1 is a vesicular-enriched protein that localizes on the cytosolic side of the vesicular membrane. (A) Superresolution image of a transfected E14.5 cortical 
neuron-cultured 5 DIV and labeled for 4′ 6‐diamidino‐2‐phenylindole (DAPI) (blue), ATAT1-GFP (green), and BDNF-mCherry (red). Scale bar is 20 m for the original image 
and 5 m for the magnified area. (B) Superresolution imagine of day 36 human projecting neurons derived from hIPSCs and immunostained for ATAT1 along with 1, 
Lamp1; 2, SV2C; and 3, synaptophysin. Arrowheads indicate codistribution of markers. Scale bar is 10 and 1 m for the original image and magnified area, respectively. 
(C) Venn diagrams of vesicular content identified by LC-MS/MS in this work and previous publications. (D) LC-MS/MS of vesicle fraction isolated from newborn mouse 
brain cortices, proteins were ranked by intensity and plotted according to their relative abundance (gray spots). Atat1 (pink) detection among proteins previously identified 
as vesicular components (purple) and molecular motors (green) (n = 3, graph represent the mean intensity value). (E) Subcellular fractionation (T, total; S1, postnuclear; 
P1, nuclear; S2, cytosol and vesicles; P2, larges membranes; S3, cytosol; and P3, vesicles) of mouse brain cortex showing predominant vesicular enrichment of Atat1, 
immunostained with antibodies (Table 1) against ATAT1 (isoform 3 and 4 corresponding to 37 and 30 kDa), histone deacetylase 6 (HDAC6), synaptophysin (SPH), synaptic 
vesicle glycoprotein 2A/B (SV2A/B), -actin, -tubulin (-tub), and histone H3 (HH3) antibodies. (F) Kymographs of ATAT1-GFP and LysoTracker or BDNF-mCherry in E14.5 
cortical neurons axons cultured 5 DIV, showing partial cotransport of Atat1 and lysosomes or BDNF-mCherry. Scale bars, 10 m (x) and 20 s (y). (G and H) Bin distribution 
and kymograph of ATAT1-GFP transport velocities in transfected E14.5 cortical neurons cultured 5 DIV (n = 5; n for anterograde =143, retrograde = 179). Scale bars, 10 m 
(x) and 20 s (y). (I) Schematic representation of truncated ATAT1 isoform four constructs. (J and K) Subcellular fractions of cultured HEK293 cells were analyzed using WB 
to detect ATAT1 truncated forms (J), vesicles/cytosol (P3/S3) ratios were quantified to identify vesicular enrichment (ratio > 1) of the various truncated ATAT1 forms (K). 
(L and M) Transfected HeLa cells with ATAT1:IRES-GFP truncated constructs were immunolabeled for acetylated -tubulin (Ac -tub, gray), total -tubulin (Tot -tub, red), 
and DAPI (blue) and analyzed for their relative acetylated -tubulin levels [Ac -tub/Tot -tub ratio, controls are set to 1, (M)]. Scale bar, 10 m. (N) WB analysis of cerebral 
cortex vesicles subjected to proteinase-K digestion. Intravesicular -synuclein is digestion resistant, while the outer vesicular membrane motor protein DIC as well as 
Atat1 were digested in an enzymatic concentration–dependent manner. Description of graphical summaries here within are histograms of means ± SEM; statistical 
analyses of (K) is one-way ANOVA and (M) is Kruskal-Wallis. Specifically [(K) P = 0.0018 and F(3,12) = 17.29; (M) P < 0.0001 and K = 83.16]. In addition, post hoc multiple 
comparisons are Holm-Sidak’s tests (K), and Dunn’s test (M);  *P < 0.05, **P < 0.01, and ****P < 0.0001. The total number of samples analyzed were four independent 
HEK293 cultures (K) and four independent HeLa cultures (M) per ATAT1 truncation construct.
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of acetylation of distal axonal MTs (Fig. 5, A and C) as a result of a 
reduction of axonal transport (Fig. 5D and fig. S6L). At this concentra-
tion, ciliobrevin D blocks both retrograde and anterograde transports 
(27); we thus specifically reduced retrograde transport by knocking 
down Lis1 in mouse cortical neurons (fig. S6, A to H). This led to a 
reduction of MT acetylation in the axon but not in the soma of these 
neurons (fig. S6, I to K). Moreover, feeding Drosophila third-instar 
larvae with ciliobrevin D (800 M) disrupted anterograde and ret-
rograde axonal transport (Fig. 5, E to G, and fig. S6A) and decreased 
MT acetylation (Fig. 5, H and I) in motoneurons in vivo to a level 
comparable with the one observed upon expression of Atat1/2 RNAi 
(Fig. 2, G and H). These results show that disrupting axonal trans-
port impairs MT acetylation, a defect that correlates with a lack of 
mobility of Atat1-enriched vesicles along the axonal MTs.
To test whether the vesicular pool of Atat1 promotes the acetyl-
ation of -tubulin in MTs, we isolated subcellular fractions from 
newborn mouse cortices and then assessed their ability to promote 
the acetylation of nonacetylated MTs isolated from HeLa cells (8), 
compared with endogenously acetylated bovine brain MTs (control) 
(Fig. 6A). We observed that most of the MT acetyltransferase activity 
was detected in the vesicular fraction (Fig. 6B), an activity that was 
lost in either vesicles isolated from Atat1 KO mice or vesicles incu-
bated without acetyl–coenzyme A (CoA), the acetyl group donor for 
Atat1-dependent MT acetylation (Fig. 6, C to E) (15). Moreover, 
the vesicular fraction was able to promote the acetylation of MTs 
over several hours in vitro, as suggested by the strong reduction of 
CoA release upon incubation with vesicles from Atat1 KO mice, as 
compared to WT control (Fig. 6F). These findings suggest that the 
Fig. 5. Ciliobrevin disrupts -tubulin acetylation and axonal transport in vitro and in vivo. (A to C) Immunolabeled cortical neurons from E14.5 mice embryos treated 
with 20 M of ciliobrevin D of control buffer 1 hour before fixation, showing total -tubulin (Tot -tub) and acetylated -tubulin (Ac -tub) in the soma (B) or distal axons 
(C) of the neurons. Scale bar, 10 m. (D to G) Axonal transport in motoneurons from synaptotagmin-GFP D. melanogaster third-instar larvae fed during 2 hours with 800 M 
of DMSO (control) or ciliobrevin D before the analysis of average SYT1-GFP vesicle velocity (D), instantaneous velocity (E), run length (F), and pausing time (G). (H and I) 
Immunolabeled motoneurons from third-instar larvae fed with 800 M of ciliobrevin D 2 hours before sacrifice, showing total -tubulin (Tot -tub) and acetylated -tubulin 
(Ac -tub). Scale bar,10 m. Description of graphical summaries here within are histograms of means ± SEM; statistical analyses of (B) and (C) are two-tailed t test, while 
those of (D) to (G) are two-tailed Mann-Whitney. Specifically, [(B) P = 0.0419 and t, df(2.051, 58); (C) P < 0.0001 and U = 699; (D) P < 0.0001 and U = 23,096; (E) P = 0.0005 and 
U = 3857 and P = 0.0209 and U = 3,293 for anterograde and retrograde, respectively; (F) P = 0.7385 and U = 37,999; (G) P < 0.0001 U = 28,877; and (I) P < 0.0001 and U = 336). 
The total number of samples analyzed was (B and C) 29 to 50 neurons from four embryos; (D to G) = 116 to 279 SYT1-GFP tracks from 6 to 8 larvae per group; and (I) 37 to 
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Fig. 6. Vesicles predominantly promote -tubulin acetylation via ATAT1. (A) WB analysis of purified tubulin from bovine brain and HeLa cells, showing acetylated 
-tubulin (Ac -tub). Ponceau red identified total -tubulin (Tot -tub) on corresponding extracts. (B and C) In vitro enzyme-linked immunosorbent assay (ELISA)–based 
-tubulin acetylation assay of polymerized nonacetylated MTs from HeLa cells; incubated with subcellular fraction (B); or with vesicular fractions isolated from WT or Atat1 KO 
mouse brain cortices with acetyl-CoA or vehicle (C). Purified bovine endogenously acetylated MTs served as control. (D and E) -Tubulin acetylation assay of in vitro 
polymerized nonacetylated MTs from HeLa cells incubated with vesicular fractions (P3) isolated from WT or Atat1 KO mouse brain cortices and acetyl-CoA or vehicle. 
Purified bovine endogenously acetylated MTs served as control. Fluorescent signal was measured for total -tubulin by using rhodamine dye and for acetylated -tubulin 
by immunolabeling. Scale bar, 2 m. (F) In vitro -tubulin acetylation assay based on CoA release from acetyl-CoA by incubating vesicles from WT or Atat1 KO mice with 
polymerized nonacetylated MTs from HeLa cells. (G) Scheme depicting the axonal transport (anterograde and retrograde) of vesicles enriched in ATAT1 at their external 
surface. The proper acetylation of MTs is linked to the axonal transport of these vesicles and we propose that axonal transport transiently disrupt the MT lattice by creating 
transient openings through which ATAT1 relocates intralumenally to promote K40 -tubulin acetylation. Description of graphical summaries here within are histograms 
of means ± SEM, while statistical analyses of (B and C) are one-way ANOVA; (D) is Kruskal-Wallis and (F) is two-way ANOVA. Specifically [(B) P < 0.0001 and F(4,35)=35.56; 
(C) P < 0.0001 and F(4,38)=158.3; (E) P < 0.0001 and K = 120.8; (F) P < 0.0001 and F(1,3360) = 8113) In addition, post hoc multiple comparisons are Sidak’s tests (B and C): 
Dunn’s test (D); ****P < 0.0001. The total number of samples analyzed were as follows: (B and C) eight subcellular brain cortical fractions from eight newborn mice; (E) = 29 
to 46 MTs, (F) 240 sample points (1/min) of purified vesicles from three WT and three Atat1 KO mouse brain cortices.
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pool of vesicular Atat1 provides an enzymatic activity that promotes 
MT acetylation and thereby fast axonal transport (Fig. 6G).
DISCUSSION
Here, we show that loss of Atat1(/2), thereby MT acetylation, 
impairs bidirectional axonal transport in mouse cortical neurons in 
culture or in organotypic slice as well as in fly larva motoneurons 
in vivo, ultimately resulting in locomotor defects in adult flies. Our 
work revealed the existence of a large pool of functional Atat1 at 
the external surface of different types of motile vesicles, including 
lysosomes and precursors of synaptic vesicles. Moreover, blocking 
MT-dependent transport impaired -tubulin acetylation, further 
suggesting that Atat1-enriched vesicles have to be transported along MT 
to promote -tubulin acetylation. Treatment with high concentration 
of ciliobrevin D (that blocks both retrograde and anterograde transport; 
Table 1. List of antibodies and their dilution used for ELISA assays, immunostainings, and/or Western blottings.  
Protein Company Cat no. WB IF ELISA
-Tubulin Sigma-Aldrich T9026 1:5000 1:2,000
-Tubulin* DSHB 12G10 1:500
/-Tubulin Cytoskeleton ATN02-A 1:150
Acetylated -tubulin Sigma-Aldrich T7451 1:15,000 1:15,000
Polyglutamylated tubulin AdipoGen AG-25B-0030 1:10,000
Glutamylated tubulin AdipoGen AG-20B-0020 1:10,000
Detyrosinated tubulin Millipore AB3201 1:1,000
∆2-Tubulin Millipore AB3203 1:2,000
Lis1 Santa Cruz Sc-393320 1:100 1:100
ATAT1 Sigma-Aldrich HPA046816 1:2000 1:120
GAPDH Millipore MAB374 1:300
LAMP1 Abcam Ab25630 1:20
Synaptophysin Synaptic Systems 101 004 1:1000
SV2C Synaptic Systems 119 204 1:500
GFP Origene TP401 1:5000
GFP Abcam Ab6673 1:1000
-Actin Sigma-Aldrich A3853 1:20,000
HDAC6 Santa Cruz Biotechnology sc-5258 1:200
GFP Molecular Probes A11122 1:1000
ATAT1 Maxence Nachury 1:1000
CSP** (cystein-string protein) DSHB DCSP-2 (D6D) 1:10
HRP Sigma-Aldrich P97899 1:1,000
FLAG Sigma-Aldrich F3165 1:1,000
Synaptophysin Sigma-Aldrich s5768 1:1,000
Histone H3 cell signaling 9715 1:5,000
Synuclein Abcam ab51252 1:5,000
DIC Millipore MAB1618 1:500
SV2*** DSHB AB 2315387 1:100
-Tubulin cell signaling 2146 1:100
Goat anti mouse Jackson ImmunoResearch Labs 115–035-003 1:10,000 1:200 1:5,000
Goat anti rabbit Jackson ImmunoResearch Labs 111-035-003 1:10,000 1:200
Donkey anti goat Jackson ImmunoResearch Labs 705-035-003 1:10,000
 *12G10 anti–-tubulin was deposited to the DSHB by J. Frankel/E.M. Nelsen (DSHB hybridoma product 12G10 anti–-tubulin).   **DCSP-2 (6D6) was deposited 
to the DSHB by S. Benzer [DSHB hybridoma product DCSP-2 (6D6)].   ***SV2 was deposited to the DSHB by K.M. Buckley (DSHB hybridoma product SV2).
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Fig. 5E) or expression of shLis1 (that blocks retrograde transport; 
fig. S6E) significantly reduced MT acetylation in the axon, while only 
ciliobrevin D treatment did so in the soma. This suggests a possible 
predominant role for the anterograde transport of Atat1-enriched 
vesicles to promote -tubulin acetylation in the soma, a hypothesis 
whose validation would require additional experiments.
Increasing MT acetylation has been shown to compensate for 
axonal transport defects in fly, mouse, and human models (6, 16). 
However, the role of Atat1 in axonal transport has been debated, 
since loss of Atat1/MEC17 expression impairs axonal transport in 
Caenorhabditis elegans neurons (28) but not in hippocampal and 
dorsal root ganglia neurons from adult mice (29). This apparent 
discrepancy may reflect different contributions of Atat1, thereby 
MT acetylation to axonal transport in distinct neuronal populations. 
It is also unexpected that, while acute deletion of Atat1 impairs MT 
acetylation, neuronal migration, and axon branching in the developing 
rodent cortex (30), Atat1 KO mice only show mild neurological 
abnormalities such as increased anxiety and impairments in mecha-
nosensation (14, 29). Such discrepancy may reflect a stronger require-
ment for Atat1 during development and early life, as suggested by 
its decreasing expression after birth in the cerebral cortex of both 
mice (30) and humans (31) (figure S7, 2018 Allen Institute for Cell 
Science. BrainSpan Atlas of the Developing Human Brain. Available 
from: brainspan.org/rnaseq/search/index.html).
Recent work performed in vitro has suggested that ATAT1 diffuses 
in the lumen of MTs where it induces acetylation of -tubulin K40 
(12). While the mode of intraluminal relocation of ATAT1 remains 
controversial (11, 12), we now suggest that motile vesicles bring 
ATAT1 in close vicinity to MTs, which is in accord with the detection 
of ATAT1 at the surface of MTs by electronic scanning microscopy 
(9). Supposing that molecular transport triggers transient MT lattice 
deformations (32, 33) and disruption (34), one can postulate that 
locally released vesicular ATAT1 could reach the MT lumen to 
acetylates -tubulin K40 in vivo via these dynamic lateral openings (35).
The results of our work, together with the observation that vesicular 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) activity contrib-
utes to local generation of adenosine triphosphate (ATP) for fast-moving 
vesicles (24), show that vesicles have on-board enzymatic machinery 
that can act locally and modulate their own transport by changing 
their molecular environment. Our work suggests, in particular, that in 
neurons, vesicle-associated enzymes can locally modify MT tracks, thus 
optimizing axonal transport. Reduced acetylation of MTs also affect 
their flexibility and thus resistance to physical breakage after repeated 
mechanical stress (10, 36), and loss of Atat1/MEC17 in C. elegans 
leads to MT instability and axonal degeneration (28). Therefore, it would 
be interesting to test whether a reduced vesicular axonal transport, as 
observed in neurodegenerative diseases (37), might contribute to the 
neurodegeneration process via curtailing the acetylation of -tubulin, 
hence leading to a global weakening and breakage of axonal MTs.
MATERIALS AND METHODS
Mice
Mice were euthanized and brain cortices were harvested either at P0 
to P2 for biochemical analysis or E14.5 for preparation of cortical 
neuronal cultures. Atat1+/− mice were used to obtain WT and KO mice 
(14). Mice were maintained with access to food and water ad libitum 
and kept at a constant temperature (19° to 22°C) and humidity (40 to 
50%) on a 12:12-hour light/dark cycle according to the guidelines 
of the Belgian Ministry of Agriculture and in agreement with the 
European Community Laboratory Animal Care and Use Regulations 
(86/609/CEE, Journal Officiel des Communautés Européennes 
L358, 18 December 1986). All experimental procedures were performed 
in strict accordance with the recommendations of the European 
Community (86/609/EEC) for care and use of laboratory animals 
under the supervision of authorized investigators.
D. melanogaster maintenance and lines
Flies were kept at a 25°C incubator with a 12-hour light and dark 
cycle. Crosses were performed at 25°C, first-instar larvae were 
transferred to a 29°C incubator until use. For axonal transport, be-
havioral experiments and immunolabeling D42-Gal4-UAS: Syt1-GFP 
or D42-Gal4 virgin females were crossed with upstream activation 
sequence (UAS)–RNAi carrying lines. For quantitative polymerase 
chain reaction (qPCR) analysis, elav-Gal4 females were crossed 
with UAS-RNAi males. All RNAi inserts sequences were validated 
by Sanger sequencing.
Drosophila lines were acquired from the Vienna Drosophila 
Resource Center (VDRC) and the Bloomington Drosophila Stock 
Center (BDSC). UAS-Syt1:GFP (BDSC 6925), UAS-RNAi Atat1 
(VDRC CG3967), UAS-RNAi Atat2 (VDRC CG17003), UAS-RNAi 
Hdac6 (BDSC 51181), and UAS-RNAi Zpg (VDRC CG10125) were 
used as control. Elav-Gal4 (BDSC 458) or D42-Gal4 (BDSC 8816) 
flies were used for specific activation of a UAS sequence in postmitotic 
neurons or motor neurons, respectively. All RNAi insert sequences 
were validated by Sanger sequencing.
Constructs
BDNF-mCherry was previously used in (24) and ATAT1-GFP (27099), 
pCALNL-DsRed (13769), and pEGFP -tubulin K40Q (105302) were 
purchased from Addgene (www.addgene.org/). pEGFP-Tub was ob-
tained from Clontech (www.takarabio.com/). pCAG mEmerald- LAMP1 
and pCAG mito-DsRED were provided by F. Polleux (Columbia Uni-
versity, New York, USA), and pCAG-iCreERT2 was provided by A. Tye 
(NIMR, UK). pCX-Cre plasmid was designed and provided by X. Morin 
(Institut de Biologie de l’Ecole Normale Superieure IBENS, France). 
ATAT1 truncation constructs, FLAG- ATAT1(amino acids 1 to 333), 
FLAG-ATAT1(amino acids 1 to 286), FLAG-ATAT1(amino acids 1 
to 242), and FLAG-ATAT1(amino acids 1 to 196) were synthesized 
as gBlocks and inserted to a pCIG2 vector. The Atat1 short hairpin RNA 
(shRNA) sequence was 5′-GCAGCAAATCATGACTATTGT-3′ (30). 
Atat1 sequence was inserted in pBS/U6- ploxPneo plasmid (provided 
by X. Coumoul). Lis1 shRNA sequence was 5′-GAGATGAACTA-
AATCGAGCTA-3′ (38) and was subcloned in pCA-b-EGFPm5 silencer 
3, a gift from M. Vermeren (King’s College London, UK). All construct 
sequences were verified by Sanger sequencing.
Cell lines culture, transfections, and drug treatment
Mouse neuroblastoma N2A cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) (Gibco) supplemented with 10% fetal calf 
serum at 37°C with 5% CO2. To test shAtat1 efficiency, we treated 
N2A cells with 4OHT (1 M) 24 and 48 hours after lipofection with 
Lipofectamine 2000 (Invitrogen), and cell lysis or fixation was 
performed 48 hours after the first treatment with 4OHT.
Neuronal cell culture
E14.5 mouse brain cortices were dissected and mechanically dissociated 
in Hanks’ balanced salt solution (HBSS) (Sigma-Aldrich, H6648) 
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supplemented with 1.5% glucose. Cells were cultured at a confluence 
of ~70% with Neurobasal Medium (Gibco, Invitrogen, 21103049) 
supplemented with 2% B27 (Gibco, Invitrogen, 17504044), 1% penicillin/
streptomycin (Gibco, Invitrogen, 15140122), and 1% GlutaMAX 
(Gibco, Invitrogen, 35050061) at 37°C. Nucleofections of E14.5 
cortical neurons were performed using Mouse Neuron Nucleofector 
Kit (VPG-1001, Lonza) according to the manufacturer’s protocol.
Human-induced pluripotent stem cell culture 
and generation of cortical projection neurons
Human embryonic stem cell research and protocols were approved by 
the Ethics Committee of the University of Liège (no. B70720096466); 
all experiments were conducted according to its guidelines. Human- 
induced pluripotent stem cell (hIPSC) line GM23446 (Coriell Institute) 
was maintained on Geltrex-coated dishes (Gibco) in DMEM/F12 
supplemented with 20% KO serum replacement (Gibco), 100 M 
nonessential amino acids (NEAA) (Gibco), 100 M 2-mercaptoethanol, 
and basic fibroblast growth factor (100 ng/ml; PeproTech, London, 
UK), conditioned on -irradiated mouse embryonic fibroblasts. Cells 
were passaged routinely with collagenase A (1 mg/ml; Roche).
Generation of human cortical neurons was performed as described 
in (39). Briefly, hiPSCs were dissociated with TrypLE (Gibco) for 
4 min at 37°C and cultured on Geltrex-coated dished in Pluripro 
medium (Cell Guidance Systems) until they reached confluency. 
Neural induction was triggered with media making use of dual SMAD 
inhibition and tankyrase inhibitor to enhance forebrain fate: DMEM/
F12 containing N2 (Gibco), B27 (Gibco), penicillin/streptomycin 
(1:100; Gibco), glucose (0.8 mg/ml; Carl Roth HN06.2), NEAA, 
GlutaMAX (Gibco), cyclic adenosine 3′,5′-monophosphate (0.15 ng/ml; 
Sigma-Aldrich, A9501-1G), 500 nM A83-01 (Miltenyi Biotec, 130-
106-274), 200 nM LDN-193189 (Miltenyi Biotec, 130-103-925), and 
2 M XAV939 (Enzo Life Sciences, BML-WN100-0005). Medium 
was changed daily, and cells were passaged at day 8 with 0.5 M 
EDTA. Cells were maintained until day 18 and replated at a density 
of 12,000 cells/cm2 in neural differentiation media containing 1:1 
DMEM/F12/Neurobasal, N2, B27, penicillin/streptomycin, glucose 
(0.8 mg/ml), NEAA, and GlutaMAX. Neural differentiation media 
were changed every other day, and Geltrex (1:100) was added 4 days 
before fixation with 4% paraformaldehyde (PFA) at day 32 to prevent 
detachment of the neurons.
Immunofluorescence
Mouse cerebral cortical neurons, N2A cells, HeLa S3 cells, and human 
projection neurons derived from hiPSCs were fixed using 4% PFA 
for 20 min at room temperature (RT) and washed with phosphate- 
buffered saline (PBS) + 0.3% Triton X-100. Antigen retrieval was 
performed for nucleofected cerebral cortical neurons using 10 mM 
sodium citrate (pH 9) for 1 hour at 60°C. After washing, neurons 
were incubated in blocking solution (PBS + 0.3% Triton X-100 + 10% 
normal donkey serum) for 1 hour at RT. Following overnight 
incubation with primary antibodies (Table 1) in blocking solution 
at 4°C, washing, incubation with secondary antibodies (PBS + 0.3% 
Triton X-100 + 1% normal donkey serum) at RT for 1 hour, and washing, 
coverslips were mounted on a microscope slide using Mowiol.
D. melanogaster larvae were dissected in PBS to expose brain and 
motor neurons, after dissection larvae were fixed with 4% PFA for 
20 min at RT, washed with PBS + 0.2% (CSP staining) or 0.3% 
(-tubulin acetylation staining) Triton X-100, and incubated in 
blocking solution PBS and 0.2% (CSP staining) or 0.3% (-tubulin 
acetylation staining) Triton X-100 + 1% bovine serum albumin 
(BSA) for 30 min at RT. Following overnight incubation with 
primary antibodies at 4°C, washing, and incubation with secondary 
antibodies at RT for 2 hours, the larvae were mounted on a micro-
scope slide using Mowiol. After washing in PBS + 0.3% Triton X-100, 
samples were incubated in blocking solution (PBS + 5% normal 
donkey serum + 0.3% Triton X-100) for 1 hour at RT. Following 
overnight incubation with antibodies at 4°C, washing, and incubation 
with secondary antibodies at RT for 2 hours, the larvae were mounted 
on a microscope slide using Mowiol. Images were acquired with a 
Nikon A1Ti confocal microscope (60× lens) for all analyses, except 
ATAT1-GFP and BDNF-mCherry staining that was acquired with 
the Airyscan superresolution module of a Zeiss LSM 880 confocal 
microscope. HeLa cells were plated at densities of 10,000 for 96-well 
black-bottom plates. The following day, cells were transfected using 
calcium phosphate with 0.01 g/96-well plates of ATAT1:IRES-
GFP truncated-form plasmids. Twenty-four hours after transfec-
tion, cells were fixed using 4% PFA and blocked and permeabilized 
using PBS + 3% fetal bovine saline (FBS) + 0.1% Triton X-100 
for 1 hour. Following overnight incubation with primary [total 
/-tubulin (ATN02-A) and acetylated -tubulin (T9026)] anti-
bodies at 4°C, washing, and incubation with secondary antibodies 
at RT for 2 hours, cells were imaged using an IN Cell 2200 micro-
scope (GE Healthcare).
Western blotting
Mouse brain cortices from Atat1 KO mice (20) or HEK293 or N2A 
cells were homogenized on ice in radioimmunoprecipitation assay 
buffer or 320 mM sucrose, 4 mM Hepes buffer for subcellular fractions, 
with protease inhibitor cocktail (Roche, P8340 or Sigma- Aldrich, S8820) 
and 5 M trichostatin A (Sigma-Aldrich, T8552). Subsequently, samples 
were boiled and reduced by 5 min of incubation at 70°C with loading 
buffer and were loaded on SDS–polyacrylamide gel electrophoresis 
gel to be finally transferred to a nitrocellulose membrane. For -tubulin 
acetylation analysis, 2 g of protein lysate was loaded on a gel; for 
analysis of all other proteins, 30 g of lysate was used. Membranes 
were imaged using Amersham Imager 600 (General Electric, 29083461), 
and band densitometry was measured using ImageJ.
Subcellular fractionation
Subcellular fractionation of a frozen mouse brain cortex or cultured 
HEK293 cells was performed as previously described (24).
MS analysis
All chemicals were purchased from Sigma-Aldrich unless stated 
otherwise. Pellets from three independent samples of vesicles isolated 
from the brain cortex of WT or Atat1 KO mice were solubilized 
using 5% SDS. Samples were then loaded onto the commercial 
S-Trap columns (ProtiFi, USA); for washing the detergents, reduction 
with 5 mM dithiothreitol (DTT), 10 mM iodoacetamide, and overnight 
digestion with trypsin (Promega) at 50:1 protein:trypsin ratio. Eluted 
peptides were dried using a vacuum centrifuge and stored in −80°C. 
Ultra LC/MS grade solvents were used for all chromatographic steps. 
Each sample was loaded using splitless nano ultraperformance LC 
(UPLC) (10 kpsi nanoACQUITY; Waters Corporation, Milford, MA, 
USA). The mobile phase was as follows: (A) H2O + 0.1% formic 
acid and (B) acetonitrile + 0.1% formic acid. Desalting of the sam-
ples was performed online using a Reversed-Phase Symmetry C18 
trapping column (internal diameter of 180 m, 20 mm in length, 
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and 5 m particle size; Waters Corporation). The peptides were then 
separated using a T3 High Strength Silica nanocolumn (internal 
diameter of 75 m, 250 mm in length, and 1.8-m particle size; Waters 
Corporation) at 0.35 l/min. Peptides were eluted from the column 
into the mass spectrometer using the following gradient: 4 to 30% B 
in 155 minutes, 30 to 90% B in 5 min, maintained at 90% for 5 min, 
and then back to initial conditions. The nanoUPLC was coupled online 
through a nanoelectrospray ionization emitter (10-m tip; New Objec-
tive, Woburn, MA, USA) to a quadrupole orbitrap mass spectrometer 
(Q Exactive Plus, Thermo Fisher Scientific), using a FlexIon nano-
spray apparatus (Proxeon). Data were acquired in a data-dependent 
acquisition mode, using a top 10 method. MS1 resolution was set to 
70,000 [at 200 mass/charge ratio (m/z)], mass range of 300 to 1650 m/z, 
and AGC of 3e6, and maximum injection time was set to 60 ms. MS2 
resolution was set to 17,500, quadrupole isolation 1.7 m/z, AGC of 1e5, 
dynamic exclusion of 60 s, and maximum injection time of 60 ms. 
Raw data were processed with MaxQuant v1.6.0.16. The data were 
searched with the Andromeda search engine against the SwisssProt 
human proteome database appended with common lab protein con-
taminants and the following modifications: carbamidomethyl on C 
and oxidation of M. Quantification was based on the Label-free quan-
titation method, based on unique peptides. t test with the Holm-Sidak 
method for multiple comparison was used for determination of sta-
tistical significance after logarithmic transformation. GO data analysis 
of the differentially detected proteins was done using GOrilla tool 
(40) (http://cbl-gorilla.cs.technion.ac.il), using two ranked lists and 
a P value of 10 × 10−3 as threshold.
Proteinase K sensitivity assay
Proteinase K sensitivity assay was performed as previously described 
(26). Fifty micrograms of vesicles (P3) were incubated with increasing 
concentration of proteinase K to reach a final concentration of 0, 0.05, 
0.25, 1.25, and 6.25 g/l in digestion buffer (10 mM Hepes, 10 mM 
KCL, 2 mM EGTA, and 300 mM sucrose) in a total volume of 50 l, 
for 30 min at 37°C. To end the reactions, 5 mM phenylmethylsulfonyl 
fluoride (PMSF) with Laemmli buffer, followed by immediate boiling 
and reduction of the samples in 95°C for 5 min.
Microfluidics device fabrication and axonal transport 
recordings in mice cortical neurons and Drosophila  
third-instar larvae
Microfluidics devices were prepared as described in (41). Axonal 
transport recording was performed after 5 DIV, as previously described 
(16), using an inverted confocal microscope (Nikon, A1Ti), at a 600-ms 
interval for 60 s using 60× lens. For cell culture, the recording 
microscope chamber was heated at 37°C and supplied with 5% CO2.
Locomotor activity and climbing assay
Larval locomotion assays were performed by placing third-instar 
D. melanogaster larvae in the center of 15-cm petri dishes coated 
with 3% agar (42). Millimeter paper was glued below each 15-cm petri 
dish to quantify distance traveled. Crawling speed was extrapolated 
from distance traveled in 1 min; peristaltic activity was defined as 
complete posteroanterior contraction of the larvae in 1 min. Climbing 
assay for adult flies was performed as previously described in (43). 
Ten flies per group were allowed to climb an empty polystyrene 
tube for 1 min in three sequential assays. Climbing index was defined 
as average ratio successful climbs over 15 cm of the total number of 
flies in a group.
Lysosome transport analysis in organotypic slice
Mice purchased from Janvier were anesthetized with isoflurane 
(Abbott Laboratories) in an oxygen carrier before the administration 
of temgesic (Schering-Plough). Endotoxin-free plasmids were injected 
into lateral ventricles of E14.5 mouse embryo forebrains using a 
FemtoJet microinjector (Eppendorf) with 0.1% fast green for visual-
ization. Injection was followed by electroporation (5 pulses of 24 mV 
at 50-ms intervals for 950 ms) using platinum electrodes (Sonidel, 
catalog no. CUY650P3) connected to an electroporator (ECM 830, 
BTX). Embryos were coelectroporated with tamoxifen-inducible 
CreERT2 expressing plasmid along with two Cre-dependent constructs 
expressing DsRed and shAtat1/sh-scrambled and with LAMP1-Emerald– 
expressing plasmid. After electroporation, embryos were placed back 
in the abdominal cavity. For injection, 4OHT and progesterone 
were dissolved in ethanol 100% at concentrations of 20 and 10 mg/ml, 
respectively, and then diluted with nine volumes of corn oil (Sigma- 
Aldrich). Diluted tamoxifen solution (2 mg/ml, 100 l per mouse) 
was intraperitoneally injected three times at E17, E18, and P1, and 
pups brains were dissected at P2. Brains were embedded in agarose 
4% HBSS solution and cut into coronal sections (300 m) using a 
vibratome (Leica VT1000S, Leica Microsystems). The slices were 
placed on Matrigel-coated (Corning) MatTek glass-bottom dishes 
and covered with half-diluted Matrigel with supplemented Neuro-
basal culture medium. Sections were incubated for 30 min at 37°C 
before imaging. Time-lapse imaging was performed on a Zeiss 
Super Resolution LSM 880 Airyscan Elyra S1 (×63 magnification) at a 
500-ms interval for 60 s at the corpus callosum midline. The re-
coding microscope chamber was heated at 37°C and supplied with 
5% CO2.
qPCR analysis
Ten adult fly heads were collected in TRIzol Reagent (Ambion, Life 
Technologies), followed by RNA extraction performed using the 
manufacturer’s instructions. After deoxyribonuclease treatment 
(Roche), 1 g of RNA was reverse-transcribed with RevertAid 
Reverse Transcriptase (Fermentas). qPCR was performed using a 
LightCycler 480 (Roche), with SYBR Green mix according to the 
manufacturer’s instructions (Roche). Analysis was done using 2-CT 
method after defining primer efficiencies, Rpl13 and Pgk served for 
normalization (44). The following primers were used: Rpl13, AGGAG-
GCGCAAGAAATC (forward) and CTTGCTGCGGTACTCCTT-
GAG (reverse); Pgk, TCCTGAAGGTCCTCAACAACATG (forward) 
and TCCACCAGTTTCTCGACGATCT (reverse); Atat1, CAGTC-
CCGCACGCTGACGAG (forward) and ACGCGCATGGTGGAG-
CAGAC (reverse); Atat2, TCCCAAGTCAAGGGAGACAC (forward) 
and TGCGGAAAGAGGTGCTTAAT (reverse); and Hdac6, CAAG-
CCCAAAGTCAAGCACT (forward) and ACCCAGTTCTCCCCCGTC 
(reverse).
Ciliobrevin treatment
Drug treatments of cortical neuronal cultures were performed 
using 20 M (Sigma-Aldrich 250401) diluted in dimethyl sulfoxide 
(DMSO) for 2 hours. For third-instar larva, drugs were fed in 10% 
sucrose solution supplemented with either 1 mM TBA (Sigma- 
Aldrich, SML0044) or 800 M Ciliobrevin D and DMSO for 30 min 
and 2 hours, respectively.
Purification of tubulin from mouse brains or HeLa cells
Nonacetylated -tubulin was obtained from HeLa S3 cells (American 
Type Culture Collection, CCL-2.2TM) for in vitro acetylation assays 
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or from WT and Atat1 KO mouse brains for in vitro transport assay 
according to the protocol adapted from (45). Cells were lysed in 
BRB80 [80 mM K− Pipes (pH 6.8), 1 mM MgCl2, and 1 mM EGTA] 
supplemented with 1 mM -mercaptoethanol, 1 mM PMSF, and 
protease inhibitors at 4°C. The soluble fraction was obtained by 
ultracentrifugation, followed by tubulin polymerization at 30°C min 
by adding 1 mM guanosine triphosphate (GTP) and 30% glycerol. 
MTs were pelleted by ultracentrifugation at 30°C for 30 min and 
depolymerized in BRB80 at 4°C; soluble tubulin was clarified by 
ultracentrifugation at 4°C. The second polymerization round was 
performed for 30 min at 30°C in the presence of high-molarity 
Pipes to remove mitogen-activated proteins; the MT pellet was 
sedimented by ultracentrifugation. MTs were then depolymerized in 
BRB80 at 4°C, and soluble tubulin was clarified and snap-frozen.
In vitro -tubulin acetylation assays
Half-area 96-well plates (Greiner, 674061) were coated with 5-g 
tubulin from HeLa cells or bovine brain (Cytoskeleton, catalog no. 
HTS02-A) in 25 l of ultrapure water for 2.5 hours at 37°C, followed 
by blocking (PBS + 3% BSA + 3% skim milk + 3% FBS) for 1 hour at 
37°C, and washing with PBS + 0.05% Tween 20. Twenty-five micro-
grams of the total, S2, S3, or P3 fractions isolated from the P0 mouse 
brain cortex were diluted in 2× histone acetyltransferase (HAT) 
buffer (Sigma-Aldrich, EPI001A) supplemented with protease inhibitor 
cocktail, 5 M trichostatin, and 50 M acetyl-CoA (Sigma-Aldrich, 
A2056) or vehicle (H20) were added per well for incubation of 2 hours 
at 37°C with shaking at 100 revolutions per minute. The wells were 
washed and incubated overnight with acetylated -tubulin antibody 
(1:2000) in blocking buffer (PBS + 0.05% Tween 20 + 3% BSA) at 
4°C, and wells were washed and incubated for 2 hours at 37°C with 
peroxidase-conjugated goat anti-mouse antibody (1:5000) in antibody 
blocking buffer; following another wash, the samples were incubated 
with trimethylboron/E (Merck Millipore, ES001), and the reaction 
was stopped with H2SO4.
CoA release was measured using HAT activity colorimetric assay 
kit (Sigma-Aldrich, EPI001), as indicated by the manufacturer’s 
instructions. Twenty-five micrograms of P3 fraction were incubated 
with 5 g of tubulin in black-bottom Clear plate (Greiner, 655090) 
for 4 hours, and signal was measured every minute.
In vitro MT-dependent transport assay
WT or Atat1 KO mouse brain was fractionated in vesicle buffer 
[10 mM Hepes-KOH, 175 mM l-aspartic acid, 65 mM taurine, 85 mM 
betaine, 25 mM glycine, 6.5 mM MgCl2, 5 mM EGTA, 0.5 mM 
d-glucose, 1.5 mM CaCl2, and 20 mM DTT (pH 7.2), with protease 
inhibitors], using increasing centrifugation speed with a final sucrose 
gradient step to isolate motility vesicles as described in (23). 
Rhodamine-labeled seeds were prepared by incubating a mix of 
rhodamine labeled with unlabeled purified tubulin from bovine 
brain (Cytoskeleton, catalog no. HTS02-A) or HeLa cells (isolated 
as described above) at a ratio of 1:10 for 1 hour at 37°C. The elongation 
was carried in GTP-BRB80 buffer (80 mM Pipes, 1 mM MgCl2, 1 mM 
EGTA, and 1 mM GTP) for 30 min at 37°C, followed by incubation 
for 20 min with 50 M Taxol to stabilize MTs.
The in vitro polymerized rhodamine-labeled MTs from WT or 
Atat1 KO mouse brains were seeded in a flow chamber and purified 
vesicles diluted in motility buffer [BRB80, 0.5% Pluronic F127, 1 mM 
Taxol, BSA in BRB80 (10 mg/ml), 1 M DTT, glucose oxidase (0.5 mg/ml), 
20 mM Mg-ATP, glucose (15 mg/ml), and catalase (470 U/ml)] were 
labeled with the green fluorescent lipophilic carbocyanine [DiOC18(3), 
Thermo Fisher Scientific] tracer, loaded in the chambers with 
50 M acetyl-CoA or vehicle, to acquire using a total internal reflection 
fluorescence (TIRF) microscope. For immunofluorescence analysis, 
MTs were fixed after the assay with 100% methanol for 10 min 
at −20°C, then incubated in blocking solution (PBS + 1% BSA) with 
acetylated -tubulin antibody (1:10,000) and goat anti-mouse Alexa 
647 antibody (1:1000) for 2 hours at RT. Recordings were performed 
by using a TIRF microscope (Nikon, Eclipse Ti), at 200-ms intervals, 
using 60× lens.
Quantification of MT acetylation levels  
using immunofluorescence
Fluorescence intensity levels were measured by Fiji (https://imagej.net/
Fiji/Downloads). Regions of interest of 30 m long for D. melanogaster, 
or the complete length for in vitro polymerized MTs, accounting for 
the full width of the motoneurons/MTs were used. The levels of 
acetylated -tubulin and total -tubulin levels were extracted from 
mean intensity levels. Background levels were subtracted, and the 
ratio of acetylated -tubulin/tubulin was calculated.
Analysis of MT-dependent transport
Kymographs were generated for single blind analysis using ImageJ 
plugin-KymoToolBox (fabrice.cordelieres@curie.u-psud.fr). For 
D. melanogaster analysis, StackReg plugin was used to align frames. 
Vesicles were considered stationary if speed was lower than 0.1 m/s.
Statistics
All experiments (except WB and quantitative reverse transcription 
PCR analyses) were performed under single-blinded condition, and 
statistical analyses were generated with GraphPad Prism Software 
6.0 or GraphPad Prism Software 7.0 for proteomic analysis.
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